Nitin Jain, MD | Authors

Chronic Lymphocytic Leukemia With Deletion 17p: Emerging Treatment Options

November 15, 2012

One strategy would be to consider “early treatment” for patients with deletion 17p, with the goal being to delay disease progression. This strategy is currently being explored in several prospective clinical trials employing treatment regimens such as FCR, lenalidomide (Revlimid), alemtuzumab (Campath), ofatumumab (Arzerra), and others.